Aurolife Pharma Recalls Fexofenadine Hydrochloride Tablets Due to Impurity Failures
Aurolife Pharma is recalling specific lots of Fexofenadine Hydrochloride 180 mg tablets because they failed impurity and degradation specifications.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II. Per the rubric, FDA Class II recalls with potential for adverse health consequences are rated as Severe (4).
Plain-English summary
Aurolife Pharma, LLC is recalling Fexofenadine Hydrochloride Tablets USP, 180 mg, in 30-count and 15-count cartons. The affected products are distributed by McKesson and are identified by specific lot numbers and expiration dates. The recall is being conducted because the tablets failed to meet impurities and degradation specifications.
The recall covers 11,928 cartons of the 30-count package (Lot 067180016B, Exp 05/21) and 288 cartons of the 15-count package (Lot 067180024F1, Exp 07/21). These products were distributed nationwide in the United States.
Consumers who have these specific products should stop using them and contact their healthcare provider or pharmacist for guidance. The recall is classified as FDA Class II, indicating a reasonable probability that the use of the product could cause temporary or medically reversible adverse health consequences.
The recalled product
- Product
- Fexofenadine Hydrochloride Tablets USP, 180 mg, packaged in a) 30-count carton (NDC 70677-0008-2) and b) 15-count carton (NDC 70677-0008-1), sunmark, Distributed by McKesson, One Post Street, San Francisco, CA 94104.
- Manufacturer
- Aurolife Pharma, LLC
- Category
- Drug — Prescription Medication
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot #s: a) 067180016B
- Exp 05/21 and b) 067180024F1
- Exp 07/21
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 11 recalled by Aurolife Pharma, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 11 products in this recall →Related recalls
Same manufacturer · Aurolife Pharma, LLC
See all →- ModerateGlycopyrrolate Tablets Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2023-06-28
- HighGlycopyrrolate Tablets Recalled for Failed Impurities and Degradation Specifications
FDA (Drugs) · 2022-12-28
- HighGlycopyrrolate Tablets Recalled Due to Glass Pieces in Sealed Bottles
FDA (Drugs) · 2022-04-06
- SevereAurolife Recalls Fexofenadine Hydrochloride Tablets Due to Impurity Failures
FDA (Drugs) · 2019-09-25
- SevereAurolife Pharma Recalls Fexofenadine HCL Tablets Due to Impurity Failures
FDA (Drugs) · 2019-09-25
Same hazard · impurity
See all →- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17